Mercilon

Desogestrel/Ethinylestradiol, the active ingredients in Mercilon, are a combined oral contraceptive presented as a 0.15 mg/0.02 mg tablet for oral use. It prevents pregnancy in women of reproductive age.

GNH USA supplies Mercilon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mercilon is a combined hormonal contraceptive that acts on the reproductive endocrine system to prevent unintended pregnancy. - Pregnancy prevention: provides reliable hormonal contraception to prevent conception. - Family planning: enables women to control the timing of pregnancy. - Ovulation suppression: inhibits ovulation to reduce the risk of fertilization.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: temporary discomfort in the breasts. - Headache: occasional tension‑type headaches. - Breakthrough bleeding: spotting between periods. - Weight gain: modest fluid retention. - Mood changes: irritability or mild mood swings.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Arterial thrombosis: stroke or myocardial infarction. - Hypertension: significant increase in blood pressure. - Hepatic adenoma: benign liver tumor. - Severe allergic reaction: anaphylaxis or angioedema. - Visual disturbances: sudden loss of vision or blurred sight.

Before initiating therapy, consider the following precautions: - Contraindicated in pregnancy: product is Category X and must not be used. - Avoid in smokers over 35 years: increased risk of thrombotic events. - Assess cardiovascular risk: history of thrombosis, hypertension, or clotting disorders. - Monitor liver function: drug is metabolised hepatically and may exacerbate liver disease. - Evaluate blood pressure: may cause modest elevation. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Mercilon may interact with several drug classes, altering its efficacy or safety profile. Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): reduce contraceptive effectiveness. - Strong CYP3A4 inducers (e.g., rifampicin, griseofulvin): lower hormone levels. - Protease inhibitors (e.g., ritonavir): may increase hormone concentrations. - St. John’s wort: decreases plasma hormone levels. Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., ampicillin): may slightly diminish contraceptive effect. - Antifungals (e.g., ketoconazole): can increase hormone exposure. - Diuretics: may exacerbate blood‑pressure changes. - SSRIs: may intensify mood‑related side effects.